Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases

@article{Lin2020MolecularME,
  title={Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases},
  author={Shen Lin and Runnan Shen and Xushun Guo},
  journal={bioRxiv},
  year={2020}
}
An anti-HIV drug named Kaletra, composed of two protease inhibitors, ritonavir and lopinavir, might have therapeutic effect on coronavirus diseases like Wuhan pneumonia. In this study, we built the structure models of two Wuhan pneumonia coronavirus proteases, coronavirus endopeptidase C30 and papain like viral protease, by homology modeling, followed by docking ritonavir and lopinavir to the protease models, respectively. In all the simulations, the binding between ritonavir and coronavirus… 

Figures from this paper

Potential Drugs for Treating COVID-19 Infection
TLDR
This review article summarizes and reiterates drugs that are potentially efficient against COVID-19 and examines both pharmaceutical efficacy and safety for CO VID-19 treatment in several countries.
Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2
TLDR
A series of peptides that can strongly bind to SARS-CoV-2 RBD are designed in computational experiments, which support the high reasonability of the designed binders, which not only recapitulated the critical native binding interactions but also introduced new favorable interactions to enhance binding.
Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation
TLDR
Light is shed on the structure-based design of natural flavonoids as anti-SARS-CoV-2 drugs targeting the nsp16/10 complex and the high stability of acaciin-nsp16 complex with binding energy of −110 kJ/mol is suggested.
De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2
TLDR
This study demonstrates a new avenue to utilize computationally designed peptide motifs to treat the COVID-19 disease by blocking the critical spike-RBD and hACE2 interactions.
What are the drugs having potential against COVID-19?
  • K. Kucukoglu, Nagihan Faydalı, D. Bul
  • Medicine, Biology
    Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
  • 2020
TLDR
All treatment options available against COVID-19 pneumonia are focused on and a great effort is made to develop effective specific therapeutic drugs, vaccines, and/or treatment strategies against these diseases.
The broad-spectrum antiviral recommendations for drug discovery against COVID-19
TLDR
Different antivirals, including interferons, ribavirin, lopinavir, and monoclonal antibodies, could be the potent therapeutic agents against COVID-19 and it is recommended that these proteases, inhibitors, and antibodies could be a good therapeutic option in drug discovery to control the newly emerged coronavirus.
Experimental Pharmacotherapy for COVID-19: The Latest Advances
TLDR
The main aim of this review is to synthesize the available information and evidence on both repositioned and experimental drugs for the treatment of COVID-19, focusing on the need to exercise caution on the use of unproven medical therapies.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
TLDR
The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS and shows that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome.
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
TLDR
The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission.
A pneumonia outbreak associated with a new coronavirus of probable bat origin
TLDR
Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Pharmacologic treatment of SARS: current knowledge and recommendations.
  • D. Tai
  • Medicine
    Annals of the Academy of Medicine, Singapore
  • 2007
TLDR
Kaletra (400 mg ritonavir and 100 mg lopinavir), a protease inhibitor used in the treatment of human immunodeficiency virus infection, may be considered for early treatment of SARS patients, preferably in a randomised double-blind placebo-controlled clinical trial setting.
Origin and evolution of pathogenic coronaviruses
TLDR
The viral factors that enabled the emergence of diseases such as severe acute respiratory syndrome and Middle East respiratory syndrome are explored and the diversity and potential of bat-borne coronaviruses are highlighted.
Antiviral Treatment Guidelines for Middle East Respiratory Syndrome
TLDR
These guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020
  • Peng Wu, Xinxin Hao, G. Leung
  • Medicine
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
  • 2020
TLDR
A novel coronavirus (2019-nCoV) causing severe acute respiratory disease emerged recently in Wuhan, China and a risk of fatality among hospitalised cases is estimated at 14% (95% confidence interval: 3.9–32%).
...
...